ASCENT-03: Sacituzumab Govitecan as First Line Treatment for Patients With Triple Negative Breast Cancer
Condition: Breast Cancer
Sponsor: Gilead Sciences
Protocol GS-US-592-6238: A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1
Patients eligible for participation in this study will have locally advanced and inoperable or metastatic triple negative breast cancer without having received prior treatment in the advanced or metastatic setting. Eligible patients' cancer can be positive or negative for expression of PD-L1.
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.